15:01 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Araclon to begin Phase II trial of AD vaccine

This month, Araclon Biotech S.L. (Zaragoza, Spain) plans to begin enrollment in a Phase II trial of ABvac40 to treat patients with "very early stages" of Alzheimer's disease (AD). The placebo-controlled, European trial will establish...
07:00 , Aug 15, 2016 |  BC Week In Review  |  Clinical News

ABvac40: Phase I data

A double-blind Phase I trial in 24 patients with mild to moderate AD showed that there were no significant differences in adverse effects between subcutaneous ABvac40 and placebo. Data were presented at the Alzheimer’s Association...